(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Why ordering takeout or calling the dog walker might lead to a happier relationship - 2At least 11 killed in South Africa mass shooting
- 3Cognizant Couture d: A Survey of \Moral Decisions and Sharp Looks\ Maintainable Style
- 4Find the Interesting Universe of Computerized reasoning: the Capability of man-made intelligence
- 5Step by step instructions to Contrast Lab Precious stones and Normal Jewels
- Choosing the Ideal Bed for Quality Rest and Solace
- Weeks-Long Australian LNG Outage Will Further Tighten Supply
- A definitive Manual for the Over-Ear Earphones
- Figure out How to Use Your Nursing Abilities for Better Compensation
- The most effective method to Pick the Ideal Lab Precious stone Wedding band
- Warming winters lead to more nitrate pollution in the drinking water near farms
- Vote in favor of Your #1 Instructive Toy: Learning and Tomfoolery Joined
- 5 Side interests That Work on Psychological wellness
- Iran war pushes Germany's deficit to 4.2% as growth outlook is cut by 50%
